Menu
homepage-header-image2

A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators

Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to address unmet needs in orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders.

Albireo’s clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a third product candidate for which an application for regulatory approval has been submitted in Japan. Albireo’s lead product candidate, A4250, is nearing initiation of Phase 3 clinical development in patients with progressive familial intrahepatic cholestasis (PFIC).

For more information, read Albireo’s corporate backgrounder.

Albireo Homepage